TTNP Key Statistics, Chart & Performance
The current stock price of TTNP is 4.61 USD. In the past month the price increased by 9.76%. In the past year, price decreased by -13.02%.
TTNP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.02 | 998.29B | ||
| JNJ | JOHNSON & JOHNSON | 19.89 | 497.30B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.30B | ||
| PFE | PFIZER INC | 8.05 | 146.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.40B | ||
| ZTS | ZOETIS INC | 20.59 | 57.54B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.83 | 23.31B | ||
| VTRS | VIATRIS INC | 5.4 | 14.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.52 | 11.70B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.24B |
Related stock screener links
About TTNP
Company Profile
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
Company Info
TITAN PHARMACEUTICALS INC
Suite 505, 400 Oyster Point Blvd
San Francisco CALIFORNIA 94080 US
CEO: Marc Rubin
Employees: 4
Phone: 14152444990
TITAN PHARMACEUTICALS INC / TTNP FAQ
What does TTNP do?
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
Can you provide the latest stock price for TITAN PHARMACEUTICALS INC?
The current stock price of TTNP is 4.61 USD. The price decreased by -3.76% in the last trading session.
What is the dividend status of TITAN PHARMACEUTICALS INC?
TTNP does not pay a dividend.
What is the ChartMill rating of TITAN PHARMACEUTICALS INC stock?
TTNP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of TTNP stock?
TITAN PHARMACEUTICALS INC (TTNP) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in TITAN PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TTNP.
Can you provide the upcoming earnings date for TITAN PHARMACEUTICALS INC?
TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2026-01-01.
TTNP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 69.92% of all stocks are doing better.
TTNP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TTNP. TTNP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TTNP Financial Highlights
Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161% | ||
| ROE | -192.87% | ||
| Debt/Equity | 0 |